219 related articles for article (PubMed ID: 23201087)
1. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
[TBL] [Abstract][Full Text] [Related]
2. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
[TBL] [Abstract][Full Text] [Related]
3. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
[TBL] [Abstract][Full Text] [Related]
5. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
[TBL] [Abstract][Full Text] [Related]
12. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
14. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
15. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.
Buzoianu AD; Militaru FC; Vesa SC; Trifa AP; Crişan S
Blood Cells Mol Dis; 2013 Mar; 50(3):166-70. PubMed ID: 23159639
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
[TBL] [Abstract][Full Text] [Related]
18. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
19. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Kalpana SR; Bharath G; Manjunath CN; Christopher R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
